Because AMPs are already used in topical nasal antimicrobials in the treatment of nasal or paranasal cavity infections (sinusitis, maxillary, otitis media) [46,47], it is conceivable that abundantly produced OMVs, by very efficient AMP sequestration, may decrease the pharmacokinetics of these compounds. The gene discussed is ADSL; the disease is sinusitis.